Myrobalan Therapeutics
Medford, United States · Biotechnology · 21 employees
Myrobalan Therapeutics is a preclinical stage biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and CNS conditions. Myrobalan applies deep knowledge of neurological processes such as demyelination and neuroinflammation, and innovative drug discovery tools, to cre
Funding history
- Series seed — $850K — Mar 2025
- Series series a — Undisclosed — Jan 2024
Recent signals
- Mar 13, 2025: Raised $850K in Series seed
- Oct 31, 2024: Myrobalan Therapeutics Appoints Dr. Robin Kleiman as Chief Scientific Officer
- Jan 10, 2024: Raised funding in Series series a
See plans & pricing → Track Myrobalan Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.